Mutual of America Capital Management LLC Sells 329 Shares of DaVita Inc. (NYSE:DVA)

Mutual of America Capital Management LLC decreased its holdings in DaVita Inc. (NYSE:DVA) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,233 shares of the company’s stock after selling 329 shares during the period. Mutual of America Capital Management LLC’s holdings in DaVita were worth $758,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. State of Michigan Retirement System lifted its holdings in shares of DaVita by 0.6% in the 4th quarter. State of Michigan Retirement System now owns 15,939 shares of the company’s stock valued at $1,670,000 after acquiring an additional 100 shares during the last quarter. Treasurer of the State of North Carolina lifted its stake in DaVita by 0.5% in the third quarter. Treasurer of the State of North Carolina now owns 24,503 shares of the company’s stock worth $2,316,000 after purchasing an additional 123 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in DaVita by 3.2% in the third quarter. Daiwa Securities Group Inc. now owns 4,631 shares of the company’s stock worth $438,000 after purchasing an additional 144 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in DaVita by 1.0% in the third quarter. PNC Financial Services Group Inc. now owns 15,088 shares of the company’s stock worth $1,426,000 after purchasing an additional 153 shares during the last quarter. Finally, New Mexico Educational Retirement Board lifted its stake in DaVita by 7.4% in the third quarter. New Mexico Educational Retirement Board now owns 2,886 shares of the company’s stock worth $273,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

DVA has been the subject of several research analyst reports. Truist Financial lifted their price target on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday, February 20th. Barclays started coverage on shares of DaVita in a report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price objective on the stock. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 16th. UBS Group lifted their price objective on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Finally, TheStreet raised shares of DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.50.

DaVita Trading Up 3.7 %

NYSE:DVA opened at $132.52 on Tuesday. The company has a market capitalization of $11.62 billion, a P/E ratio of 17.91, a PEG ratio of 1.14 and a beta of 1.04. The firm has a fifty day simple moving average of $131.04 and a 200-day simple moving average of $109.53. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $141.54. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.53 by $0.34. The company had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.11 earnings per share. On average, equities research analysts anticipate that DaVita Inc. will post 9.23 earnings per share for the current year.

Insiders Place Their Bets

In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the transaction, the chief executive officer now owns 488,697 shares in the company, valued at $61,629,578.67. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, COO Michael David Staffieri sold 29,488 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the completion of the sale, the chief operating officer now owns 37,687 shares of the company’s stock, valued at $4,515,279.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Javier Rodriguez sold 67,603 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the sale, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The disclosure for this sale can be found here. Over the last quarter, insiders sold 134,540 shares of company stock worth $16,551,071. Company insiders own 1.40% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.